DGDonghao Guo

Donghao Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Donghao Guo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Ya Miao

    Department of Geriatrics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China

    4 shared publications
  • Wei Li

    Department of Geriatrics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China

    3 shared publications
  • Yuan Zhong

    Department of Geriatrics, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

    3 shared publications
  • Junjie Wang

    Department of Pediatric Endocrinology, Quanzhou Women’s and Children’s Hospital

    2 shared publications
  • Qinjie Li

    Department of Geriatrics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China

    2 shared publications
  • Xiaohui Huang

    Department of Operating Room, Quanzhou Women’s and Children’s Hospital

    2 shared publications

Latest Publications

  • Fabkin Promoted Osteoclasts Mature and Bone Loss in OVX ‐Induced Osteoporosis Mice

    by Chenhao Pan, Shixun Li, Changchun Li, Wing Cheuk Ko, Taihe Liu, Haoxian Liu, Donghao Guo, Yue Ding

    Osteoporosis (OP) is a chronic skeletal disorder characterized by reduced bone mineral density and increased fracture risk, particularly from hip fractures linked to a 20%–24% increased mortality risk within the first year. Current therapies remained inadequate in addressing metabolic drivers, which prompted exploration of novel targets. Fabkin, a recently identified hormonal complex comprising fatty acid‐binding protein 4 (FABP4), nucleoside diphosphate kinase (NDPK), and adenosine kinase (ADK), was implicated in metabolic and inflammatory signaling. It was suggested that Fabkin could promote Ca 2+ influx and the release of inflammatory factors via the PKA pathway. However, its role in bone loss remained unclear. To investigate the role of Fabkin in OP, an ovariectomy (OVX)‐induced murine model was used to simulate estrogen‐deficient osteoporosis. FABP4‐KO mice were generated to disrupt Fabkin formation, and bone microarchitecture was assessed using micro‐CT and histological staining. Osteoclastogenesis assays in vitro were conducted using bone marrow‐derived macrophages (BMDMs) treated with recombinant Fabkin components. Western blotting and RT‐qPCR were performed to analyze key signaling pathways involved in osteoclast differentiation, particularly MAPK and NF‐κB. Immunofluorescence analysis revealed an increase in Fabkin expression in the bone marrow of OVX mice. OVX‐induced osteoporosis was significantly attenuated in FABP4‐KO mice with higher BMD. TRAP staining showed a reduction in osteoclast numbers in FABP4‐KO mice. In vitro, Fabkin treatment significantly enhanced osteoclast differentiation and bone resorption, whereas FABP4 deficiency inhibited osteoclast formation. Molecular analysis revealed that Fabkin promoted osteoclastogenesis via the RANKL‐induced MAPK and NF‐κB signaling pathways. These findings suggested that FABP4 might directly exacerbate osteoclastogenesis by acting as a Fabkin complex instead of a lipid regulator.


  • Open Access

    Albumin: a novel biomarker for predicting intraoperative hypothermia in HSCR

    by Xiaohui Huang, Mobai Ren, Junrong Pan, Ene Huang, Yanhong Li, Donghao Guo, Junjie Wang

    Intraoperative hypothermia is a significant life-threatening emergency during surgery in patients with Hirschsprung's disease (HSCR). The aim of this study is to explore the risk factors and predictors of intraoperative hypothermia in HSCR patients. This cohort comprised 85 patients with HSCR who underwent surgery at Quanzhou Children's Hospital and the patients were divided into the intraoperative non-hypothermia group and the intraoperative hypothermia group. The study compared the characteristics of two groups and used univariate and multiple logistic regression analyses to assess the potential risk factors for intraoperative hypothermia. Models were adjusted for covariates, and interaction terms were evaluated for albumin (ALB) and intraoperative hypothermia. Subgroup analysis included stratification by sex and age. ROC analysis was applied to determine the optimal threshold for ALB. In this retrospective study, 71 patients had intraoperative non-hypothermia and 14 patients had intraoperative hypothermia (83.5% versus 16.5%). Comparing the clinical characteristics between two groups, baseline core temperature, ALB and alkaline phosphatase (p < .001, p = .001 and p = .036, respectively) showed significant differences. Univariate logistic regression showed that baseline core temperature (OR = 0.001, 95%CI = 0.000-0.024, p < .001), ALB (OR = 0.820, 95%CI = 0.679-0.972, p = .028) and gamma-glutamyl transferase (OR = 1.017, 95%CI = 1.001-1.035, p = .043) had significant associations with intraoperative hypothermia. Multiple logistic regression showed that both ALB (OR = 0.782, 95%CI = 0.611-0.965, p = .031) and baseline core temperature (OR = 0.001, 95%CI = 0.000-0.019, p < .001) were negatively associated with intraoperative hypothermia. The relationship between ALB and intraoperative hypothermia remained significant after adjusting for covariates. ROC analysis identified 41.45 g/L as the optimal threshold of ALB for predicting intraoperative hypothermia, with a sensitivity of 85.71% and a specificity of 64.79%. ALB is an independent risk factor for intraoperative hypothermia in HSCR patients. Further investments are required to explore its mechanisms.


  • Open Access

    Predictors and a novel predictive model for intravascular immunoglobulin resistance in Kawasaki disease

    by Junjie Wang, Xiaohui Huang, Donghao Guo

    Background: Early identification of intravenous immunoglobulin (IVIG) resistance contributes to better management of Kawasaki disease (KD). This study aims to establish an effective prediction model for IVIG resistance in the Chinese population. Methods: A total of 658 eligible patients diagnosed with KD were enrolled in this study, with 461 in the training cohort and 197 in the validation cohort. The demographic characteristics and potential risk factors were compared between IVIG-responsive and resistant groups. Predictors were selected by the Akaike information criterion. The nomogram’s performance was evaluated by calibration curve, decision curve analysis, and operating characteristic curve. Results: White blood cell counts (WBC), neutrophil-lymphocyte ratio (N/L ratio), hematocrit (HCT), albumin (ALB), total bilirubin (TBIL), lactate dehydrogenase (LDH), and creatinine (Cr) were detected as predictors of IVIG resistance. A predictive nomogram incorporating these predictors was constructed using the training cohort. The calibration curve and decision curve analysis showed good discrimination and calibration of the proposed nomogram in both training and validation sets, and the area under the receiver operating characteristic curve (AUROC) in both sets was 75.8% and 74.2%, respectively. Conclusion: This study identified WBC, N/L ratio, HCT, ALB, TBIL, LDH, and Cr as predictors for IVIG resistance in patients with KD. The proposed novel nomogram with a high level of accuracy and reliability may benefit clinical decision-making upon treatment initiation.


  • Open Access

    mTOR-dependent TFEB activation and TFEB overexpression enhance autophagy-lysosome pathway and ameliorate Alzheimer's disease-like pathology in diabetic encephalopathy

    by Lizhen Cheng, Yixin Chen, Donghao Guo, Yuan Zhong, Wei Li, Yijia Lin, Ya Miao

    Background: Diabetic encephalopathy (DE) is a complication of type 2 diabetes mellitus (T2DM) that features Alzheimer's disease (AD)-like pathology, which can be degraded by the autophagy-lysosome pathway (ALP). Since transcription factor EB (TFEB) is a master regulator of ALP, TFEB-mediated ALP activation might have a therapeutic effect on DE, but this has yet to be investigated. Methods: We established T2DM mouse models and cultured HT22 cells under high-glucose (HG) conditions to confirm the role of ALP in DE. To further investigate this, both mice and HT22 cells were treated with 3-methyladenine (3-MA). We also analyzed the content of TFEB in the nucleus and cytoplasm to evaluate its role in ALP. To confirm the effect of TFEB activation at the post-translational level in DE, we used rapamycin to inhibit the mechanistic target of rapamycin (mTOR). We transduced both mice and cells with TFEB vector to evaluate the therapeutic effect of TFEB overexpression on DE. Conversely, we conducted TFEB knockdown to verify its role in DE in another direction. Results: We found that T2DM mice experienced compromised cognitive function, while HG-cultured HT22 cells exhibited increased cell apoptosis. Additionally, both T2DM mice and HG-cultured HT22 cells showed impaired ALP and heavier AD-like pathology. This pathology worsened after treatment with 3-MA. We also observed decreased TFEB nuclear translocation in both T2DM mice and HG-cultured HT22 cells. However, inhibiting mTOR with rapamycin or overexpressing TFEB increased TFEB nuclear translocation, enhancing the clearance of ALP-targeted AD-like pathology. This contributed to protection against neuronal apoptosis and alleviation of cognitive impairment. Conversely, TFEB knockdown lessened ALP-targeted AD-like pathology clearance and had a negative impact on DE. Conclusion: Our findings suggest that impaired ALP is responsible for the aggravation of AD-like pathology in T2DM. We propose that mTOR-dependent TFEB activation and TFEB overexpression are promising therapeutic strategies for DE, as they enhance the clearance of ALP-targeted AD-like pathology and alleviate neuronal apoptosis. Our study provides insight into the underlying mechanisms of DE and offers potential avenues for the development of new treatments for this debilitating complication of T2DM. Graphic


  • Open Access

    Azithromycin use prior to ICU admission is associated with a lower short-term mortality for critically ill acute exacerbations of chronic obstructive pulmonary disease patients: A retrospective cohort study

    by Xuequn Guo, Hongsheng Lin, Donghao Guo, Qiu Luo

    Azithromycin was thought to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) by anti-microbial and anti-inflammatory effects. However, it′s value in the treatment of critically ill patients with AECOPD before ICU admission remains unclear. Our study aimed to find whether azithromycin use prior to ICU admission leads to better clinical outcomes for those individuals. 533 critically ill patients with AECOPD from the MIMIC-IV database were included. Univariate followed multivariate logistic regression was used to select risk factors for short-term mortality. The multivariable logistic regression models were implemented to investigate the association between azithromycin use before ICU admission and short-term mortality. Lower short-term mortality was observed in the azithromycin group ( p = .021), independent of differences in demographic data and other clinical outcomes ( p>.05). Azithromycin use before ICU admission was proved to have a decreased short-term mortality by multivariable logistic regression ( p<.05). The results remained consistent after being stratified by age, SOFA scores, pH, and cancer diagnosis. Azithromycin use prior to ICU admission was associated with lower short-term mortality for critically ill AECOPD patients.


  • Open Access

    A Nomogram Based on Comorbidities and Infection Location to Predict 30 Days Mortality of Immunocompromised Patients in ICU: A Retrospective Cohort Study

    by Xuequn Guo, Donghao Guo

    Background: The existing comorbidity indexes, like Charlson Comorbidity Index (CCI) and the Elixhauser Comorbidity Index (ECI), do not take infection factors into account for critically ill patients with immunocompromise, bringing about a decrease of prediction accuracy. Therefore, we attempted to incorporate infection location into the analysis to construct a rapid comorbidity scoring system independent of laboratory tests. Methods: Data were extracted from the Multiparameter Intelligent Monitoring in Intensive Care III database. A total of 3904 critically ill patients with immunocompromise admitted to ICU were enrolled and assigned into training or validation sets according to the date of ICU admission. The predictive nomogram was constructed in the training set based on logistic regression analysis and then undergone validation in the validation set in comparison with SOFA, CCI and ECI. Results: Factors eligible for the nomogram included patient’s age, gender, ethnicity, underlying disease of immunocompromise like metastatic cancer and leukemia, possible infection on admission including pulmonary infection, urinary tract infection and blood infection, and one comorbidity, coagulopathy. The nomogram we developed exhibited better discrimination than SOFA, CCI and ECI with an area under the receiver operating characteristic curve (AUC) of 0.739 (95% CI 0.707– 0.771) and 0.746 (95% CI 0.713– 0.779) in the training and validation sets, respectively. Combining the nomogram and SOFA could bring a new prediction model with a superior predictive effect in both sets (training set AUC = 0.803 95% CI 0.777– 0.828, validation set AUC = 0.818 95% CI 0.783– 0.854). The calibration curve exhibited coherence between the nomogram and ideal observation for two cohorts (p> 0.05). Decision curve analysis revealed the clinical usefulness of the nomogram in both sets. Conclusion: We established a nomogram that could provide an accurate assessment of 30 days ICU mortality in critically ill patients with immunocompromise, which can be employed to evaluate the short-term prognosis of those patients and bring more clinical benefits without dependence on laboratory tests.


  • Open Access

    Upregulation of flavin-containing monooxygenase 3 mimics calorie restriction to retard liver aging by inducing autophagy

    by Donghao Guo, Yun Shen, Wei Li, Qinjie Li, Ya Miao, Yuan Zhong

    Flavin-containing monooxygenase 3 (FMO3) gene expression is often upregulated in long-lived murine models. However, the specific relationship between FMO3 and aging remains unknown. Here, we show that 40% calorie restriction (CR), which is considered to be one of the most robust interventions to delay aging progression, markedly upregulates FMO3. Most importantly, upregulation of hepatocyte FMO3 in murine models prevented or reversed hepatic aging. Accordingly, the upregulation of FMO3 mimicked the effects of CR: reduced serum levels of pro-inflammatory cytokine interleukin-6 and fasting insulin; relief of oxidative stress, with lower hepatic malondialdehyde levels and higher superoxide dismutase activity; reduced serum and hepatic levels of total cholesterol and triglyceride, as well as reduced lipid deposition in the liver; and diminished levels of aging-related markers β-gal and p16. There were also synergistic effects between FMO3 upregulation and CR. Inhibition of autophagy blocked the anti-aging effects of upregulation of hepatocyte FMO3, including reversing the amelioration of the serum and hepatic parameters related to inflammation, oxidative stress, lipid metabolism, liver function, and hepatocyte senescence. Our results suggest that the upregulation of FMO3 mimics CR to prevent or reverse hepatic aging by promoting autophagy.


  • Diabetes Promotes Development of Alzheimer’s Disease Through Suppression of Autophagy

    by Ya Miao, Donghao Guo, Wei Li, Yuan Zhong

    Recent studies suggest that diabetes predisposes patients to develop neurodegenerative Alzheimer’s disease (AD), although the underlying mechanisms have yet to be determined. Compromised autophagy of neuronal cells, which occurs in the early stages o


  • Open Access

    6-Bromoindirubin-3′-Oxime (6BIO) Suppresses the mTOR Pathway, Promotes Autophagy, and Exerts Anti-aging Effects in Rodent Liver

    by Donghao Guo, Yun Shen, Wei Li, Qinjie Li, Yu Zhao, Chenhao Pan, Bi Chen, Yuan Zhong, Ya Miao

    Liver aging is associated with age-related histopathological and functional changes that significantly enhance the risk of numerous diseases or disorders developing in elderly populations. 6-Bromoindirubin-3′-oxime (6BIO), a potent inhibitor of glycogen synthase kinase-3 (GSK-3), has been implicated in various age-related diseases and processes, such as tumorigenesis, neurodegeneration, and diabetes. Recent studies have also revealed that 6BIO increases autophagy in yeast, mammalian cell lines, and dopaminergic neurons, which is one of the classical mechanisms strongly associated with liver aging. However, the impact or the mechanism of action of 6BIO in liver remains entirely unknown. Here, we find that 6BIO reduces oxidative stress, improves lipid metabolism, enhances autophagy, and significantly retards liver aging via modulating the GSK-3β pathway and mTOR pathway. Our findings suggest that 6BIO could be a potential agent to protect the liver in the field of anti-aging pharmacology.